Know Cancer

forgot password

Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma

Phase 2
18 Years
Open (Enrolling)
Glioblastoma Multiforme, Gliosarcoma

Thank you

Trial Information

Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma

Inclusion Criteria:

- Patients must have recurrent histologically confirmed diagnosis of WHO grade IV
malignant glioma (glioblastoma multiforme or gliosarcoma) with no more than 3 prior

- Age ≥ 18 years.

- Karnofsky ≥ 60%.

- An interval of at least 4 weeks between either prior tumor biopsy or prior major
surgical procedure and study enrollment.

- Bi-dimensionally measurable disease as assessed by magnetic resonance imaging.

- Hemoglobin ≥9.0 g/dl, ANC ≥1500 cells/µl, Platelets ≥125,000 cells/µl (without
transfusion within 14 days before enrollment).

- Serum creatinine < 1.5 mg/dl, bilirubin < 1.5 times upper limit of normal, and serum
SGOT (AST) and SGPT (ALT) < 2.5 times upper limit of normal.

- For patients on corticosteroids, they must be on a stable dose for 1 week prior to
entry, and the dose should not be escalated over entry dose level, if clinically

- Signed informed consent approved by the Institutional Review Board.

- No evidence of active CNS hemorrhage on the baseline MRI or CT scan.

- If sexually active, patients will take contraceptive measures for the duration of
treatment as stated in the informed consent.

Exclusion Criteria:

- Pregnancy or breast-feeding.

- Baseline ECG with QTc > 0.45 second

- Co-medication that may interfere with study results; e.g. immuno-suppressive agents
other than corticosteroids.

- Thrombosis or vascular ischemic events within the last twelve months, such as deep
venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral
infarction, or myocardial infarction.

- Active infection requiring IV antibiotics 7 days before enrollment.

- History of central nervous system bleeding as defined by stroke or intraocular bleed
(including embolic stroke) within 6 months before enrollment.

- Evidence of acute intracranial hemorrhage; except for subjects with stable grade 1

- Less than 12 weeks from radiation therapy, unless progressive disease outside of the
radiation field or 2 consecutive scans or histopathologic confirmation.

- Treated previously with any c-Met or HGF targeted therapy.

- Treated previously with VEGF or VEGFR therapies, including antibodies and tyrosine
kinase inhibitors.

- Treated with thalidomide or tamoxifen within 1 week before enrollment or has not
recovered from the toxic effects of such cancer therapy.

- Treated with immunotherapeutic agents, vaccines, or MAb therapy within 4 weeks before
enrollment or have not recovered from the toxic effects of such cancer therapy.

- Treated with alkylating agents within 4 weeks before enrollment or has not recovered
from the toxic effects of such cancer therapy.

- Treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or
has not recovered from the toxic effects of such cancer therapy.

- Less than 4 weeks after surgical resection of the brain tumor or less than 2 weeks
after biopsy before enrollment or have not recovered from acute side effects of such
procedures except for neurological effects.

- Plans to receive surgery, radiation therapy or other elective surgeries during the
course of the study.

- Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,
congestive cardiac failure, myocardial infarction within 6 months before enrollment)
that could compromise participation in the study.

- Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except:
Use of low dose coumadin-type anticoagulants (≤ 2 mg PO QD) low molecular weight
heparins (LMWH), e.g. Enoxaparin sodium (Lovenox) and unfractionated heparin for
prophylaxis against central venous catheter thrombosis is allowed.

- Grade 2 or greater peripheral edema or effusion (pleural, pericardial, or ascites).

- Inability to comply with study and/or follow-up procedure.

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study.

Avastin-Specific Exclusion Criteria

Subjects meeting any of the following criteria are ineligible for study entry:

- Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg
and/or diastolic blood pressure > 100 mmHg)

- Prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to Day 1,
the day protocol therapy starts.

- History of stroke or transient ischemic attack within 6 months prior to Day 1

- Significant vascular disease (e.g. aortic aneurysm, requiring surgical repair or
recent peripheral arterial thrombosis) (within 6 months prior to Day 1).

- History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days
prior to Day 1

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to Day 1

- Serious, non-healing wound, active ulcer or untreated bone fracture

- Proteinuria as defined by ≥ +1 on urinalysis dipstick

- Known hypersensitivity to any component of Avastin

- Pregnant (positive pregnancy test) or lactation.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Radiological response rates

Outcome Description:

Radiological response rates as determined by the Modified McDonald criteria, which incorporates steroid use and clinical status in addition to the tumor response.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Katherine B Peters, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Duke University


United States: Food and Drug Administration

Study ID:




Start Date:

August 2010

Completion Date:

June 2014

Related Keywords:

  • Glioblastoma Multiforme
  • Gliosarcoma
  • glioblastoma multiforme
  • gliosarcoma
  • malignant glioma
  • glioma
  • Avastin
  • bevacizumab
  • AMG 102
  • recurrent
  • Duke
  • Pro00022491
  • Vredenburgh
  • Glioblastoma
  • Glioma
  • Gliosarcoma



The Preston Robert Tisch Brain Tumor CenterDurham, North Carolina  27710